







































































Typhoid	 fever	 continues	 to	 represent	 a	 significant	 threat	 to	 global	 health	 and	 currently	
licensed	vaccines	confer	incomplete	protection.		


















possible.	 The	 contribution	 that	 volunteers	 make	 to	 research	 of	 this	 kind	 cannot	 be	
overstated.	
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Abbreviations	 are	 defined	 at	 their	 first	 use	 within	 the	 text.	 The	 following	 is	 a	 list	 of	
abbreviations	used	within	this	thesis,	compiled	in	alphabetical	order:	
APC	 	 	 Antigen	presenting	cell	
AU		 	 	 Arbitrary	units	
B	cell	 	 	 B	lymphocyte	
BCG	vaccine	 	 Bacillus	Calmette–Guérin	vaccine	
BCR	 	 	 B-cell	receptor	
BSA		 	 	 Bovine	serum	albumin	
CCL	 	 	 Chemotaxis	chemokine	ligand	
CCR	 	 	 C-C	chemokine	receptor	
CFU	 	 	 Colony	forming	unit	
CI	 	 	 Confidence	interval	
DAPC	 	 	 Discriminant	analysis	of	principal	components	
DC		 	 	 Dendritic	cell	
EBV	 	 	 Epstein-Barr	virus	
EPI	 	 	 Expanded	Programme	on	Immunisation	
FBS	 	 	 Foetal	bovine	serum	
FOXP3	 	 	 Forkhead	box	P3	
GCP	 	 	 Good	Clinical	Practice	
GM-CSF	 	 Granulocyte	macrophage	colony-stimulating	factor	
H	antigen	 	 Protein	flagella	
HIV		 	 	 Human	immunodeficiency	virus	
IFN	 	 	 Interferon	
Ig	 	 	 Immunoglobulin	
ABBREVIATIONS	
xviii	
IL	 	 	 Interleukin	
ILC	 	 	 Innate	lymphoid	cell	
iMFI		 	 	 Integrated	mean	fluorescence	intensity	
LPS	 	 	 Lipopolysaccharide	
M	cell	 	 	 Microfold-cell	
MAdCAM-1	 	 Mucosal	addressin	cell	adhesion	molecule-1	
MAIT	cell	 	 Mucosal-associated	invariant	T	cell	
MDR	 	 	 Multidrug	resistant	
MFI	 	 	 Geometric	mean	fluorescence	intensity	
MHC	 	 	 Major	histocompatibility	complex	
MIP	 	 	 Macrophage	inflammatory	protein	
miRNA	 	 	 MicroRNA	
MMC	 	 	 Mucosal	mononuclear	cell	
NHS	 	 	 National	Health	Service	
NK	cell	 	 	 Natural	killer	cell	
NKT	cell	 	 Natural	killer	T	cell	
NRES	 	 	 United	Kingdom	National	Research	Ethics	Service	
OMPs	 	 	 Outer	membrane	proteins	
PAMP	 	 	 Pathogen	associated	molecular	pattern	
PBMC	 	 	 Peripheral	blood	mononuclear	cell	
PBS	 	 	 Phosphate	buffered	saline	
PCV	 	 	 13-valent	pneumococcal	conjugate	vaccine	
PPD	 	 	 Purified	protein	derivative	





SCV		 	 	 Salmonella	containing	vacuole	
SEB	 	 	 Staphylococcal	enterotoxin	B	
SPI	 	 	 Salmonella	Pathogeneicity	Island	
T	cell	 	 	 T	lymphocyte	
T3SS	 	 	 Type	III	secretion	system	
TCM-cell	 	 	 Central	memory	T-cell	
TCR	 	 	 T-cell	receptor	
TEM-cell	 	 	 Effector	memory	T-cell	
TEMRA-cell	 	 Terminal	effector	memory	T-cell	
TGF	 	 	 Transforming	growth	factor	
TH	cell		 	 	 Helper	CD4+	T	cell	
TLR	 	 	 Toll-like	receptor	
TNF	 	 	 Tumor	necrosis	factor	
TREG	cell	 	 	 Regulatory	T	cell	
Vi	polysaccharide	 Virulence	polysaccharide	







Salmonella	 enterica	 subspecies	 I	 serovar	 Typhi	 (S.	 Typhi)	 is	 a	 facultative	 intracellular	
pathogen	and	the	causative	agent	of	typhoid	fever.	This	bacterium	is	highly	adapted	to	its	
human	host	and	possesses	a	number	of	specialised	mechanisms,	which	combine	to	facilitate	
survival,	 replication	and	 transmission.	Disease	 is	endemic	 in	many	 resource-poor	nations,	
where	inadequate	sanitation	and	poor	food	hygiene	facilitates	faecal-oral	transmission.	




resistant	 strains	 has	 redirected	 efforts	 towards	 the	 development	 of	 new	 vaccines.	
Unfortunately,	 development	has	been	hindered	by	our	 limited	understanding	of	mucosal	





S.	 enterica	 is	 a	 facultative	 intracellular	 Gram-negative	motile	 bacillus	 which	 comprises	 6	
subspecies,	50	serogroups	and	more	than	2,600	serovars	(Issenhuth-Jeanjean	et	al.,	2014).		
Approximately	 99%	 of	 serovars	which	 cause	 illness	 in	 humans	 reside	within	 subspecies	 I	
(Desai	et	al.,	2013).	The	vast	majority	of	these	serovars	have	a	broad	host	rage	and	cause	
self-limiting	 gastroenteritis	 in	 humans.	 These	 non-typhoidal	 serovars	 actively	 induce	
inflammation	at	the	intestinal	lumen	and	outcompete	other	bacteria	through	the	extraction	
of	 inflammatory-derived	 nutrients	 (Winter	 et	 al.,	 2010).	 In	 the	 presence	 of	
immunosuppressive	 illness,	 non-typhoidal	 serovars	 can	 cause	 an	 invasive	 bloodstream	
infection	in	humans,	known	as	invasive	non-typhoidal	disease	(Feasey	et	al.,	2015).		
A	 small	 number	 of	 serovars	 are	 human-host-restricted	 and	 cause	 typhoid/paratyphoid.	
These	typhoidal	serovars	are	believed	to	have	evolved	along	four	phylogenetically	unrelated	
lineages;	S.	Typhi,	S.	Paratyphi	B	and	S.	Paratyphi	C	each	form	single	lineages,	while	the	fourth	
lineage	 is	 formed	 by	 S.	 Paratyphi	 A	 and	 S.	 Sendai	 (Selander	 et	 al.,	 1990).	 It	 is	 likely	 that	
typhoidal	 serovars	 are	 descended	 from	 organisms	 that	 once	 caused	 gastroenteritis	 in	





























and	 Dougan,	 2007).	 Alongside	 the	 core	 genome,	 there	 are	 virulence	 associated	 regions	
termed	Salmonella	Pathogenicity	 Islands	 (SPIs),	which	are	 thought	 to	have	been	acquired	
relatively	recently	through	horizontal	gene	transfer	(Hacker	and	Kaper,	2000).	SPI-1	and	SPI-
2	 encode	 type	 III	 secretion	 systems	 (T3SSs),	 these	 needle-like	 structures	 facilitate	
manipulation	of	host-cell	function	through	effector	protein	secretion	(Figure	1.3)	(Sukhan,	
2000).	SPI-7	encodes	the	capsular	Vi	polysaccharide,	which	masks	bacterial	antigens	(Nair	et	
al.,	 2004).	 The	 vast	majority	of	S.	 Typhi	 isolates	 that	have	been	 sequenced	possess	 SPI-7	
(Wain	 et	 al.,	 2005),	 which	 suggests	 that	 expression	 of	 the	 Vi	 polysaccharide	 provides	 a	












et	al.,	1989).	Flagella	are	 involved	 in	motility	and	cell	 invasion	(Grossman	et	al.,	1995).	S.	
Typhi	typically	expresses	the	H1-d	antigen;	however,	16%	of	Indonesian	isolates	alternately	
express	 the	 H1-j	 antigen	 (Grossman	 et	 al.,	 1995).	 Evidence	 suggests	 that	 isolates	 which	
express	the	H1-j	antigen	are	less	motile	and	less	invasive	than	those	which	express	the	H1-d	
antigen	 (Grossman	et	al.,	1995).	 Interestingly,	however,	H1-j	expression	 is	more	common	
among	 isolates	 collected	 from	 the	 elderly	 (Grossman	 et	 al.,	 1995).	 It	 is	 possible	 that	




facilitates	 bacterial	 adhesion	 and	 invasion	 across	 the	 intestinal	mucosa	 (Raffatellu	 et	 al.,	






antigen	 (Wilson	 et	 al.,	 2011)	 and	 the	 ligation	 of	 host-cell	 toll-like	 receptors	 (TLRs)	 via	
pathogen	associated	molecular	patterns	(PAMPs)	(Raffatellu	et	al.,	2005,	Wilson	et	al.,	2008).	







pathogenesis	 has	 been	 gathered	 from	 murine	 models	 of	 S.	 Typhimurium	 infection	 and	
models	utilising	human	cell-lines.		
Following	ingestion,	prior	to	invasion,	sufficient	numbers	of	bacteria	must	weather	gastric	
acidity	 and	 avoid	 enzymatic	 degradation.	 Individuals	 with	 impaired	 hydrochloric	 acid	
production,	either	as	a	result	of	antacid	consumption	or	gastrectomy,	are	at	increased	risk	
of	developing	disease	(Parry	et	al.,	2002).	SPI-1	plays	a	prominent	role	in	the	establishment	






closely	 and	 deliver	 antigen	 to	 underlying	 immune	 cells	 through	 transcytosis	 (Jepson	 and	











upregulation	 of	 SPI-2	 and	 reduces	 bacterial	 virulence	 (Arpaia	 et	 al.,	 2011).	 These	 data	
indicate	 that	 the	 ligation	 of	 multiple	 TLRs	 is	 required	 for	 virulence	 in	 vivo.	 Salmonellae	
typically	 infect	 a	 high	 proportion	 of	 cells	 at	 low	 levels	 (Brown	 et	 al.,	 2006).	 Intracellular	
populations	 are	 typically	 heterogeneous,	 comprising	 both	 replicating	 and	 non-replicating	
bacteria	(Helaine	et	al.,	2014).	Mathematical	models	predict	that	S.	Typhi	may	be	released	
from	the	intracellular	environment	into	the	extracellular	space	at	any	time,	independent	of	







Intracellular	 salmonellae	 may	 disseminate	 via	 lymphatics	 or	 blood	 throughout	 the	
reticuloendothelial	system	(Parry	et	al.,	2002).	Extracellular	dissemination	may	also	occur;	
however,	 within	 the	 extracellular	 compartment,	 the	 bacteria	 are	 susceptible	 to	 B-cell-





















commonly	 used	 method	 to	 inform	 diagnoses	 in	 the	 developing	 world.	 Unfortunately,	





More	 recently,	meta-regression	 has	 estimated	 that	 there	 are	 approximately	 17.8	million	




























pathogenesis,	 immunity	 and	 prophylactic	 intervention,	 in	 a	 setting	 where	 baseline	
measurements	may	be	made	and	the	exact	time	of	bacterial	challenge	is	known	(Pollard	et	








University	 of	 Maryland	 (Hornick	 et	 al.,	 2007).	 In	 this	 model,	 participants	 were	 orally	
challenged	with	virulent	S.	Typhi	strain	Ty2	suspended	 in	milk.	Two	different	strains	were	
used	 in	 this	model;	 early	 trials	 used	 a	 strain	which	was	 isolated	 in	 Kherson	 (modern	day	
Ukraine)	in	1918	(Hornick	et	al.,	2007)	and	latter	trials	used	a	strain	which	was	isolated	from	






























from	Vietnam	were	 resistant	 to	 chloramphenicol	 (Linh	 and	 Arnold,	 1975).	 Initially,	 these	
isolates	 retained	 sensitivity	 to	 co-trimoxazole,	 ampicillin	 and	 amoxicillin;	 however,	 in	 the	
1980s,	the	first	multidrug	resistance	(MDR)	isolates,	resistant	to	all	frontline	antibiotics,	were	
identified	(Bhutta	et	al.,	1991).	










and	 the	bowel,	 they	 are	 effective	within	 the	 intracellular	 compartment	 and	have	 an	oral	









been	 deemed	 clinically	 acceptable,	 has	 provided	 evidence	 supporting	 the	 safety	 of	
fluoroquinolones	 in	 children	 (Schaad	 et	 al.,	 1991,	 Schaad	 and	Wedgwood,	 1992).	 In	 one	
study,	children	aged	between	1	and	14	years	treated	with	fluoroquinolones	presented	with	





al.,	 2001).	 While	 isolates	 of	 S.	 Typhi	 have	 been	 identified	 which	 are	 fully	 resistant	 to	
ciprofloxacin,	 they	 have,	 thus	 far,	 retained	 susceptibility	 to	 ceftriaxone	 and	 azithromycin	
(Chuang	et	al.,	2009).	Ceftriaxone	is	as	effective	as	chloramphenicol	over	a	3	day	or	7	day	
course	 (Lasserre	 et	 al.,	 1991,	 Islam	 et	 al.,	 1988).	 Treatment	 of	 fluoroquinolone-resistant	











Dendritic	 cells	 (DCs)	 are	 professional	 antigen	 presenting	 cells	 (APCs),	 derived	 from	
monocytes,	which	are	believed	to	play	a	particularly	important	role	in	the	generation	of	T-
cell-mediated	 immunity	 to	 typhoid.	 Infected	 DCs	 are	 able	 to	 present	 S.	 Typhi	 antigens	
directly	sampled	from	within	their	cytoplasm	(Salerno-Goncalves	and	Sztein,	2009).	DCs	are	
also	able	to	phagocytose	S.	Typhi	infected	cells	and	present	antigens	through	suicide	cross-
presentation	 (Salerno-Goncalves	 and	 Sztein,	 2009).	DCs	may	also	 activate	 T	 cells	 through	
cytokine	production	(Salerno-Goncalves	and	Sztein,	2009,	Toapanta	et	al.,	2015).	
Controlled	 human	 infection	 has	 demonstrated	 that,	 in	 volunteers	 resistant	 to	 infection,	
monocyte	 and	 DC	 capacity	 for	 binding	 is	 increased	 immediately	 following	 challenge	
(Toapanta	et	al.,	2015).	In	contrast,	in	volunteers	susceptible	to	infection,	monocyte	and	DC	




Murine	 models	 have	 demonstrated	 that	 epithelial	 TLR-5	 ligation	 by	 flagella	 induces	
expression	 of	 chemotaxis	 chemokine	 ligand	 (CCL)20	 which	 results	 in	 the	 migration	 of	
immature	DCs	to	the	intestinal	mucosa	(Sierro	et	al.,	2001).	Controlled	human	infection	has	
demonstrated	 that,	 in	 volunteers	 susceptible	 to	 infection,	 in	 the	 days	 leading	 to	 and	
immediately	following	diagnosis	of	disease,	α4β7	is	upregulated	among	monocytes	but	not	
among	DCs	 (Toapanta	et	al.,	 2015).	No	changes	were	observed	 in	 volunteers	 resistant	 to	




Murine	 models	 of	 infection	 have	 observed	 the	 accumulation	 of	 neutrophils	 in	 Peyer’s	














M-cells,	which	overly	 Peyer’s	 patches	 in	 the	 small	 intestine,	 are	 responsible	 for	 sampling	
antigen	 from	 the	 intestinal	 lumen.	 Their	 complex	 folded	 basal	 structure	 facilitates	 close	
association	 with	 innate	 and	 adaptive	 immune	 cell	 subsets.	 DCs	 found	 at	 the	 intestinal	
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mucosa	possess	 a	 unique	morphology	which	 facilitates	 antigen	 sampling	 from	within	 the	
intestinal	lumen	(Soloff	and	Barratt-Boyes,	2010).	Gut-associated	DCs,	unlike	extra-intestinal	
DCs,	 are	 able	 to	metabolise	 vitamin	 A	 in	 order	 to	 produce	 all-trans	 retinoic	 acid,	 which	
induces	expression	of	α4β7	and	C-C	chemokine	receptor	(CCR)9	on	adaptive	immune	cells	(De	

















able	 to	 evade	 adaptive	 immune	 responses	 generated	 during	 the	 course	 of	 infection;	








unique	effector	 functions	and	both	 likely	contribute	towards	 immunity	 to	 typhoid.	The	Vi	










mechanisms	 of	 defence.	 The	 importance	 of	 intracellular	 immune	 evasion	 has	 been	
demonstrated	 by	 murine	 models	 which	 have	 demonstrated	 that	 salmonellae	which	 are	







































below	 the	 lower	 limit	 of	 detection	 (Kantele,	 1990).	 Plasma	 B	 cells	 are	 most	 abundant	
between	4	and	10	days	post-vaccination	(Kantele	et	al.,	1986,	Kantele,	1990,	Kantele	et	al.,	
1991).	Following	a	period	of	peripheral	circulation,	plasma	B	cells	are	believed	to	migrate	to	






























Losonsky	 et	 al.,	 1987,	 Jesudason	 et	 al.,	 1998,	 Herath,	 2003).	 Interestingly,	 however,	 in	
endemic	 regions,	 susceptibility	 to	 disease	 persists	 in	 the	 presence	 of	 raised	 levels	 of	
immunoglobulin	to	the	Vi	polysaccharide,	flagellin	and	LPS	(Dupont	et	al.,	1971,	Levine	et	al.,	
1978).	Controlled	human	infection	has	demonstrated	that	there	is	no	association	between	
levels	 of	 serum	 immunoglobulin	 specific	 to	 these	 antigens	 prior	 to	 challenge	 and	
susceptibility	 to	disease	 (Waddington	et	 al.,	 2014).	 Immunoglobulin	 responses	 specific	 to	
flagella	 and	 LPS	 have	 been	 observed	 in	 volunteers	 susceptible	 to	 infection	 but	 not	 in	
volunteers	 resistant	 to	 infection	 (Waddington	 et	 al.,	 2014).	 In	 this	 model,	 no	 responses	




In	 regions	 of	 endemic	 disease,	where	 S.	 Typhi	 is	 likely	 to	 be	 encountered	 intermittently,	
bactericidal	immunoglobulin	function	has	been	shown	to	increase	with	age	(Pulickal	et	al.,	
2009).	 Immunoglobulin	 generated	 through	 oral	 vaccination	with	 attenuated	 S.	 Typhi	 has	






intestinal	 fluids	 and	 stool	 following	 natural	 infection	 and	 following	 oral	 vaccination	with	
attenuated	S.	Typhi	(Forrest,	1992,	Cancellieri	and	Fara,	1985,	Herath,	2003,	Pakkanen	et	al.,	
2010).	IgA	selectively	engages	M	cells	in	order	to	more	efficiently	deliver	antigen	and	engage	
adaptive	 responses	 (Rey	 et	 al.,	 2004,	 Boullier	 et	 al.,	 2009).	 Murine	 models	 have	





through	 antigen	 presentation	 and	 cytokine	 production.	 Murine	 models	 of	 Salmonella	








Susceptibility	 to	disease	has	been	assessed	 in	wild-type,	B-cell-deficient,	 immunoglobulin-
deficient	 and	 class-switched-immunoglobulin-deficient	 mice	 immunised	 with	 live-
attenuated	Salmonella	(Nanton	et	al.,	2012).	It	was	observed	that,	while	B-cell-deficient	mice	
were	 susceptible	 to	 infection,	 wild-type,	 immunoglobulin-deficient	 and	 class-switched-
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In	 contrast	with	 B	 cells,	 T-cell	 effector	 function	 is	 not	 restricted	 to	 pathogens	within	 the	
extracellular	environment.	T	cells	recognise	peptides	displayed	by	MHC	molecules	expressed	
on	 the	 surface	 of	 host-cells.	 MHC	 class	 I	 is	 recognised	 by	 cytotoxic	 CD8+	 T	 cells	 and	 is	
expressed	on	 the	 surface	of	almost	all	 cell	 types,	 it	 is	 responsible	 for	 the	presentation	of	





responsible	 for	 the	 preservation	 long-term	 T-cell-mediated	 immunity	 to	 the	 antigen	
recognised	by	the	TCR.	
While	B-cell-mediated	immunity	can	protect	against	cell	invasion	and	disease	acquisition,	T-








T-cell	 responses	 in	 vitro	 are	 influenced	 by	 the	 nature	 of	 the	 stimulant;	 in	 particular,	 the	
dependence	 of	 soluble	 antigenic	 preparations	 on	 cross-presentation	 to	 engage	 cytotoxic	
CD8+	 T	 cells.	 Thus,	 broadly	 speaking,	 CD4+	 T	 cells	 are	 more	 likely	 to	 respond	 to	 soluble	
antigenic	preparations	than	CD8+	T	cells	(Salerno-Goncalves	et	al.,	2002,	Salerno-Goncalves	
et	al.,	2003,	Sztein,	2007).		
In	 humans,	 pro-inflammatory	 cytokine	 production	 has	 been	 observed	 amongst	 CD4+	 and	
CD8+	T	cells	following	ex	vivo	stimulation	with	soluble	S.	Typhi	antigens	(Sztein	et	al.,	1994,	
Salerno-Goncalves	 et	 al.,	 2002,	 Salerno-Goncalves	 et	 al.,	 2003,	 Salerno-Goncalves	 et	 al.,	
2004).	 Following	 oral	 vaccination	with	 attenuated	S.	 Typhi,	 CD4+	 and	 CD8+	 T	 cells,	which	
produce	IFN-γ	in	response	to	LPS	and	flagella	antigens,	persist	in	peripheral	blood	for	up	to	
56	days	(Sztein	et	al.,	1994,	Salerno-Goncalves	et	al.,	2002,	Salerno-Goncalves	et	al.,	2003).		
Multiphasic	 CD8+	 central	memory	 T	 (TCM)-cell,	 effector	memory	 T	 (TEM)-cell	 and	 terminal	
effector	 memory	 T	 (TEMRA)-cell	 responses,	 which	 persist	 for	 at	 least	 2	 years,	 have	 been	
described	 following	 oral	 vaccination	 with	 attenuated	 S.	 Typhi	 (Salerno-Goncalves	 et	 al.,	
2010).	 CD8+	 TCM	 cells,	 TEM	 cells	 and	 TEMRA	 cells,	 stimulated	 with	 S.	 Typhi-infected	 EBV-
transformed	 host	 B	 cells,	 have	 demonstrated	 the	 capacity	 to	 simultaneously	 produce	 as	
many	 as	 six	 cytokines/chemokines	 (Salerno-Goncalves	 et	 al.,	 2010,	McArthur	 and	 Sztein,	
2012).	 Polyfunctional	 T	 cells	 –	 those	 which	 simultaneous	 produce	 multiple	
cytokines/chemokines	 –	have	been	 shown	 to	 correlate	with	 vaccine	mediated	protection	
against	 other	 intracellular	 infections	 (Darrah	 et	 al.,	 2007,	 Kannanganat	 et	 al.,	 2007).	 The	
generation	 of	 polyfunctional	 T	 cells	 has	 also	 been	 observed	 following	 environmental	
exposure	 to	 intracellular	 pathogens,	 including	 human	 immunodeficiency	 virus	 (HIV)	 and	




associated	 with	 protection	 against	 disease	 when	 volunteers	 are	 challenged	 with	
approximately	 103	 CFU	 (Fresnay	 et	 al.,	 2016),	 but	 are	 associated	 with	 an	 increased	




(Fresnay	 et	 al.,	 2017).	 They	 suggest	 that	 the	 higher	 dose	 inoculum	 generates	 stronger	




exposure	 to	 other	 components	 of	 the	 human	 immune	 system,	 including	 inflammatory	




























increased	 capacity	 for	mucosal	 homing;	 they	 simultaneously	 express	 high	 levels	 of	 α4β7,	
intermediate	levels	of	CCR9	and	low	levels	of	CD103	(Salerno-Goncalves	et	al.,	2005).	It	has	























models	have	demonstrated	 that	γδ	T-cell	depletion	 reduces	 the	50%	 lethal	dose	300-fold	
(Mixter	et	al.,	1994)	and	that	 inhibition	of	γδ	T-cell	migration	 to	 the	 intestinal	epithelium	
increases	disease	severity	(Edelblum	et	al.,	2015).	
Controlled	human	infection	has	demonstrated	that,	 in	volunteers	susceptible	to	 infection,	
during	 the	 course	 of	 infection,	 there	 is	 a	 sharp	 decline	 in	 the	 number	 of	 MAIT	 cells	 in	
peripheral	 blood	 (Salerno-Goncalves	 et	 al.,	 2017).	 Interestingly,	 in	 these	 volunteers,	 the	
frequency	 of	 activated	 MAIT	 cells	 expressing	 CCR9	 increased	 significantly	 following	
diagnosis,	much	more	so	in	volunteers	challenged	with	103	CFU	than	in	volunteers	challenged	









It	 has	 been	 suggested	 that	 heightened	 inflammation	 may	 actually	 favour	 systemic	
dissemination	 (Fresnay	et	al.,	2017).	Murine	data	 indicate	 that	 the	balance	between	pro-




Typhi-infected	 EBV-transformed	 host	 B	 cells	 (McArthur	 et	 al.,	 2015).	 Controlled	 human	
infection	has	demonstrated	that,	in	response	to	challenge,	the	expression	of	α4β7	is	reduced	






Immunological	 studies	have	demonstrated	 that	 innate	 immune	 cells,	 upon	exposure	 to	 a	











2014),	 supports	 the	 notion	 that	 innate	 immune	 cells	 are	 also	 able	 to	 generate	memory	
through	a	process	termed	trained	immunity.		
While	 adaptive	 immune	 responses	 are	 the	 result	 of	 receptor	 gene	 rearrangement	 and	
affinity	maturation,	 the	 generation	of	 innate	 immune	memory	 is	 the	 result	 of	 epigenetic	
reprogramming.	 Typically,	 genes	 which	 encode	 inflammatory	 factors	 are	 packaged	 in	 a	
repressed	configuration,	inhibiting	transcriptional	activation	(Smale	et	al.,	2014);	however,	
upon	activation,	stimulation-responsive	transcription	factors	and	promoters	are	recruited	to	
these	 loci,	 resulting	 in	 increased	 accessibility	 and	 facilitating	 high-level	 gene	 expression	
(Ghisletti	 et	 al.,	 2010,	 Heinz	 et	 al.,	 2010,	 Barozzi	 et	 al.,	 2014,	 Smale	 and	 Natoli,	 2014).	
Following	 stimulation,	 trained	 immunity	 is	 generated	 through	 a	 process,	which	 is	 in-part	
dependent	 upon	 changes	 in	 cellular	 metabolism	 as	 well	 as	 structural	 histone	 and	 DNA	
modification	(Krawczyk	et	al.,	2010,	Pantel	et	al.,	2014).	These	changes	facilitate	enhanced	
transcriptional	 access,	 resulting	 in	 stronger	 cellular	 responses	 following	 re-stimulation	
(Ramirez-Carrozzi	et	al.,	2006,	Ramirez-Carrozzi	et	al.,	2009).	Since	microRNAs	(miRNAs)	are	
known	to	persist	for	long	periods	with	the	cytoplasm	and	since	myeloid	cells	have	a	limited	











date,	 no	data	has	 been	presented	which	demonstrates	 that	 these	 kind	of	 immunological	
observations	are	clinically	relevant	in	humans	(Pollard	et	al.,	2017).	Since	data	indicate	that	
monocytes	 typically	 only	 persist	 in	 circulation	 for	 a	 single	 day	 (Yona	 et	 al.,	 2013),	 it	 is	
reasonable	to	assume	that	trained	immunity	is	imprinted	at	the	progenitor	level.	Due	to	the	










individual’s	 response	 to	 vaccination	 through	 TLR	 engagement	 (Oh	 et	 al.,	 2014).	 It	 has,	
therefore,	been	 suggested	 that	 intestinal	 commensals	may	be	considered	as	endogenous	
adjuvants.	In	view	of	these	data,	it	is	reasonable	to	hypothesise	that	a	live-attenuated	orally-





been	 observed	 (Reller	 et	 al.,	 2003).	 Towards	 the	 end	 of	 the	 19th	 century,	 resource-rich	
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nations	 made	 efforts	 to	 increase	 the	 availability	 of	 clean,	 or	 chlorinated	 water,	 and	 to	
improve	 sanitation	 infrastructure	 (Smith	 and	 Tennant,	 1899).	 The	 implantation	 of	 these	
measures	was	associated	with	a	marked	decline	 in	 the	 incidence	of	 typhoid	 fever	 (Smith,	
1920).	Typhoid	fever	continues	to	persist	 in	many	resource-poor	nations,	where	access	to	
treated	water	is	limited	and/or	where	living	conditions	are	unsanitary	(Figure	1.5).	The	risk	









variation	 in	 the	 supply	of	 clean	water	 (Siddiqui	et	al.,	2006,	Crump	et	al.,	2008).	 In	 some	








Since	 S.	 Typhi	 is	 restricted	 to	 its	 human	 host,	 efficacious	 vaccination	 may	 lead	 to	 the	
eradication	of	disease.	The	successful	eradication	of	smallpox	was,	 in	part,	due	to	human	
host	 restricted	 nature	 of	 the	 small	 pox	 virus	 (Metzger	 et	 al.,	 2015).	 In	 the	 face	 of	 rising	
antimicrobial	resistance,	the	WHO	has	recommended	the	introduction	of	typhoid	vaccines	




In	1896,	 the	 first	 inactivated	whole-cell	 typhoid	vaccine	was	 introduced.	This	vaccine	was	
administered	parenterally,	as	a	single	dose	of	 inactivated	preserved	preparations	of	wild-
type	S.	Typhi	 in	 liquid	suspension	(Groschel	and	Hornick,	1981).	A	trial	conducted	 in	1953	
demonstrated	 that	 heat-inactivated	 phenol-preserved	 preparations	 were	 superior	 to	










Vaccine	type	 Brand	name	 Manufacturer	 Number	of	doses	 Field	trial	efficacy	 Minimum	administration	age	
Inactivated	whole	cell	
(Injectable)	 N/A	 No	longer	in	production	 2	 ~60–80%	 N/A	
Live-attenuated	
(Oral)		 Vivotif	 Crucell		 3-4	 ~60–80%	 ≥6	years	
Vi	polysaccharide	
(Injectable)	
Typhim	Vi	 Sanofi	Pasteur	 1	 ~55–72%	 ≥2	years	
Typherix	 GlaxoSmithKline	 1	 61%	 ≥2	years	
Typbar	 Bharat	Biotech	 1	 No	data	available	 ≥2	years	
Vax-TyVi	 Finlay	Instituto	 1	 No	data	available	 ≥2	years	
TyViVac	 Dalat	Vaccine	Company	 1	 No	data	available	 ≥2	years	
BioTyphi	 BioMed	 1	 No	data	available	 ≥2	years	
Vi	polysaccharide	
combination	(Injectable)	
Hepatyrix	 GlaxoSmithKline	 1	 No	data	available	 ≥15	years	
ViATIM	 Sanofi	Pasteur	 1	 No	data	available	 ≥16	years	
Vi	polysaccharide	
conjugate	(Injectable)	
Pedatyph	 BioMed	 2	 No	data	available	 ≥3	months	



























Two	 subsequent	 field	 trials	 demonstrated	 the	 variable	 efficacy	 of	 this	 vaccine;	 a	 96%	







Vaccination	 is	dependent	upon	the	administration	of	 three	spaced	doses	and	 the	vaccine	
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possesses	 only	modest	 immunogenicity	 (Anwar	 et	 al.,	 2014).	 In	 addition,	 children	 in	 the	
developing	world	tend	to	be	hyporesponsive	to	orally-administered	vaccines	(Levine	et	al.,	





et	 al.,	 1994).	 This	 vaccine	 is	 administered	 parenterally	 as	 a	 single	 dose	 of	 purified	 Vi	
polysaccharide	in	liquid	suspension.		




heat-killed	 vaccine	 preparations	 (Wong	 et	 al.,	 1974).	 It	 was	 later	 determined	 that	
conformational	 changes	 brought	 about	 during	 isolation	 of	 the	 polysaccharide	 were	
responsible	 for	 previous	 vaccine	 failure	 (Landy	 et	 al.,	 1961).	 A	 refined	 method	 of	




efficacy	 was	 demonstrated	 over	 17	 months	 in	 Nepal	 (Acharya	 et	 al.,	 1987)	 and	 a	 77%	
protective	efficacy	over	21	months	in	South	Africa	(Klugman	et	al.,	1987).	A	recent	systematic	
review	calculated	a	cumulative	efficacy	of	55%	3	years	following	vaccination	(Anwar	et	al.,	







polysaccharide	 vaccines,	 immune	 responses	 are	 T-cell	 independent;	 thus,	 no	 immune	
memory	 is	 generated	 and	 responses	 may	 not	 be	 boosted	 through	 repeated	 vaccination	
(Lesinski	and	Westerink,	2001).	Although	trials	have	not	been	conducted	in	young	children,	
vaccination	with	purified	Vi	polysaccharide	is	unlikely	to	be	efficacious	due	to	the	immaturity	




which	 provide	 education	 in	 sanitation	 and	 food	 hygiene	 could	 dramatically	 reduce	 the	
burden	of	typhoid	fever	 in	endemic	regions	(2008).	Unfortunately,	 the	 implementation	of	







Vaccine	type	 Name	 Manufacturer	 Number	of	doses	 Field	trial	efficacy	 Minimum	administration	age	
Live-attenuated	
(Oral)		
CVD	908	 University	of	Maryland	 1	 No	data	available	 No	data	available	
CVD	908-htrA	 University	of	Maryland	 1	 No	data	available	 No	data	available	
CVD	909	 University	of	Maryland	 1	 No	data	available	 No	data	available	
Ty800	 University	of	Maryland	 1	 No	data	available	 No	data	available	
M01ZH09	 Massachusetts	General	Hospital		 1	 No	data	available	 No	data	available	
Vi-conjugate	
(Injectable)	
Vi-TT	 BioMed	 1	 100%	 ≥6	months	
Vi-rEPA	 NIH	 2	 89%	 ≥2	years	












Orally-administered	 vaccines	 are	 able	 to	 generate	 responses	 tailored	 to	 defence	 at	 the	
intestinal	mucosa.	 The	 orally-administered	 Ty21a	 vaccine	 is	more	well-tolerated	 clinically	
and	easier	 to	administer	 than	parenterally-administered	alternatives	 (Anwar	et	al.,	2014).	












In	 an	effort	 to	prevent	 vaccinaemia,	CVD	908	was	 further	 attenuated;	CVD	908-htrA	was	
engineered	 through	 deletion	 of	 htrA.	 The	 ΔhtrA	 mutation	 prevents	 expression	 of	 a	 heat	






the	 Vi	 polysaccharide	 by	 switching	 the	 tviA	 promoter,	 which	 regulates	 Vi	 polysaccharide	
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demonstrates	 that	 CVD	 909	 generates	 memory	 B	 cells	 specific	 to	 the	 Vi	 polysaccharide	
(Wahid	et	al.,	2011).		
Ty800	









ssaV	 (Kirkpatrick	 et	 al.,	 2005).	 The	 ΔaroC	 mutation	 disrupts	 synthesis	 of	 chorismic	 acid,	

















A	 number	 of	 parenterally-administered	 Vi	 polysaccharide	 protein	 conjugate	 vaccines	 are	
currently	 in	 development.	 The	 conjugation	 of	 polysaccharide	 to	 protein	 facilitates	 T-cell	
engagement,	 enabling	 immunoglobulin	 affinity	 maturation,	 immunoglobulin	 isotype	
switching	and	the	development	immunological	memory	in	both	adults	and	children	(Levine	
et	 al.,	 2001,	 Pulickal	 and	 Pollard,	 2007).	 The	 development	 of	 this	 technology	 has	
revolutionised	vaccine	development.	
Conjugation	of	 the	Vi	 polysaccharide	 to	 a	 nontoxic,	 recombinant	 protein	 –	Pseudomonas	
aeruginosa	 exotoxin	 –	 was	 first	 described	 in	 1987	 (Szu	 et	 al.,	 1987).	 Administration	 of	
multiple	doses	of	Vi	polysaccharide	protein	conjugate	vaccines	enhances	immunity	and	does	
not	 result	 in	 immune	 hypo-responsiveness,	 which	 is	 associated	 with	 administration	 of	
multiple	 doses	 of	 unconjugated	Vi	 polysaccharide	 vaccines	 (An	 et	 al.,	 2012).	 Based	 upon	
































increased	 further	 (Bhutta	 et	 al.,	 2014).	 It	 should	 also	 be	 noted	 that,	 in	 both	 adults	 and	
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children,	6	months	following	administration	of	the	final	dose,	 levels	of	 immunoglobulin	 in	






of	 5	 μg	Vi-TT,	 administered	 6	weeks	 apart,	was	 shown	 to	 be	well-tolerated	with	 a	 100%	
protective	efficacy	in	children	aged	between	6	months	and	12	years,	over	12	months	(Mitra	
et	al.,	2016).	Seroconversion,	defined	as	a	4-fold	increase	in	levels	of	IgG	specific	to	the	Vi	
polysaccharide,	 was	 observed	 in	 100%	 of	 vaccinated	 volunteers	 at	 6	 weeks	 and	 83%	 of	
vaccinated	volunteers	at	12	months	(Mitra	et	al.,	2016).		
More	 recently,	 controlled	human	 infection	has	been	used	 to	 assess	 the	efficacy	of	Vi-TT.	




rEPA	 (Lin	et	al.,	2001,	Mai	et	al.,	2003),	but	 less	 than	 that	 reported	 in	 field	 trials	of	Vi-TT	
(Mitra	et	al.,	2016).	Interestingly,	as	was	the	case	for	Vi-rEPA	vaccinated	volunteers	(Lin	et	










Vi-polysaccharide	 (Hashimoto	 and	 Khan,	 1997).	 In	 addition,	 Vi	 polysaccharide	 negative	








































Project	title	 REC	 Reference	 Results	
Mucosal	Responses	to	
Oral	Vaccination	 North	West	–	Liverpool	Central	 10/H1005/20	 Chapter	3	
Understanding	
Immunity	to	Typhoid	 North	West	–	Liverpool	Central	 13/NW/0282	 Chapter	4	
Non-specific	Effects	of	






and	poster	 advertisement	 at	 the	University	 of	 Liverpool,	 the	 Liverpool	 School	 of	 Tropical	




















































Volunteers	 were	 vaccinated	 with	 Ty21a	 (Vivotif;	 Crucell).	 Volunteers	 were	 instructed	 to	
consume	 a	 single	 enteric-coated	 vaccine	 capsule	 (Table	 2.3)	 on	 days	 0,	 2	 and	 4,	












































the	 Department	 of	 Gastroenterology	 at	 the	 Royal	 Liverpool	 University	 Hospital	 for	
endoscopy	 at	 approximately	 0800	 hours.	 Consent	 for	 endoscopic	 procedures	 was	
reconfirmed	 by	 the	 endoscopist,	 according	 to	 standard	 National	 Health	 Service	 (NHS)	
procedures.	 Sedation	was	 offered	 to	 all	 volunteers;	 those	who	 requested	 sedation	were	
given	up	to	5	mg	midazolam	intravenously.	O2	was	administered	at	a	rate	2	L/minute	via	a	
nasal	 cannula	 and	 O2	 saturation	was	monitored	 throughout	 the	 procedure	 using	 a	 pulse	
oximeter.	
Gastroscopy	
12-15	 single-bite	 biopsies	 were	 acquired	 from	 the	 duodenum	 at	 D2-D3	 using	 Single-Use	
Radial	Jaw	4	large	capacity	forceps.	Biopsies	were	placed	directly	 into	50	mL	Falcon	tubes	



























































































































PBS-/-	 in	 sterile	 untreated	 96-well	 plates.	 LB-agar	 plates	 were	 divided	 into	 four	 sections,	
which	were	 labelled	103,	 104,	 105	 and	106.	 Three	10	µL	 spots	were	 added	 to	each	of	 the	
corresponding	 sections	and	 the	plate	allowed	 to	dry.	Plates	were	 inverted	and	 incubated	
overnight	at	37°C	in	5%	CO2.	The	next	day	the	largest	number	of	countable	colonies	in	a	single	
section	were	enumerated	and	the	following	equation	used	to	calculate	CFU/µL:	
!"#$%&	()	*(+(,-%.	*(",/%01".2%,.-(,	3(+"#%	2+4/%0 	×	6789:7;<	=>?:;@ 	= BCD/µG	 		
2.5.4. Serum	isolation	







were	diluted	with	an	equal	 volume	of	Dulbecco's	PBS	and	 layered	on	either	 Lymphoprep	
(Chapter	 3)	 or	 Histopaque-1077	 (Chapter	 4)	 in	 50	 mL	 Falcon	 tubes.	 Samples	 were	 then	
centrifuged	at	800	g	for	18	minutes	at	room	temperature	without	brake.	Cells	were	isolated	
using	 a	 sterile	 Pasteur	 pipette,	washed	 twice	 (centrifuged	 at	 250	 g	 for	 10	minutes)	 with	
Dulbecco's	PBS-/-	and	resuspended	in	1mL	complete	medium.	A	sample	of	the	cell	suspension	
was	diluted	1:1	by	adding	10	µL	of	the	cell	suspension	to	10	µL	0.4%	Trypan	Blue.	The	number	











g	 for	 18	minutes	 at	 room	 temperature	without	 brake.	 Cells	were	 isolated	 using	 a	 sterile	



























centrifuged	at	330	g	 for	10	minutes,	 the	 supernatant	 removed	and	 the	 cells	 in	each	well	
resuspended	in	100	µL	prewarmed	complete	medium.	




and	 placed	 at	 37°C	 for	 30	minutes	 at	 a	 45°	 angle	with	 shaking	 (220	 rpm).	 Biopsies	were	
mechanically	disrupted	by	passing	 the	 tissue	suspension	 through	a	16-gauge	blunt-ended	
needle	five	times.	The	suspension	was	then	passed	through	a	70	µm	cell	strainer	and	the	cell	
suspension	 stored	on	 ice.	Tissue	 fragments	 captured	 in	 the	cell	 strainer	were	 transferred	
back	 into	the	original	 tube	by	rinsing	the	cell	strainer	with	prewarmed	CII-S	medium.	The	









The	 following	day,	 cells	were	harvested	 from	wells	 and	 the	wells	washed	with	 1	mL	R20	
medium.	Cell	suspensions	were	then	centrifuged	at	400	g	for	10	minutes	and	resuspended	
in	1	mL	complete	medium.	A	sample	of	the	cell	suspension	was	diluted	1:1	by	adding	10	µL	








Study	reference	 Name	 Description	 Manufacturer	 Per	test	
Chapter	5	 LIVE/DEAD	 Pacific	Orange	 LifeTechnologies	 0.02	µL	
	






Study	reference	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Chapter	5	
CD14	 MφP9	 PerCP/Cy5.5	 BD	Biosciences	 3.5	µL	
CD16	 FcγRIII	 APC/Cy7	 BioLegend	 3.5	µL	
CD64	 HI10a	 BV605	 BioLegend	 3.5	µL	
CD18	 TS1/18	 PE/Cy7	 BioLegend	 3.5	µL	
CD11b	 ICRF44	 AF700	 BD	Biosciences	 3.5	µL	
CD11c	 Bu15	 Pacific	Blue	 BioLegend	 3.5	µL	
CD123	 6H6	 BV711	 BioLegend	 3.5	µL	
CD206	 19.2	 PE/CF594	 BD	Biosciences	 3.5	µL	
CD284	 HTA125	 APC	 BioLegend	 3.5	µL	
CD285	 624915	 FITC	 R&D	Systems	 3.5	µL	
CD303	 201A	 PE	 BioLegend	 3.5	µL	
CD161	 L243	 BV785	 BioLegend	 3.5	µL	
	
Cells	were	 incubated	for	20	minutes	at	room	temperature	 in	the	absence	of	 light.	150	µL	
wash	buffer	was	added	to	each	well	and	the	plates	centrifuged	at	330	g	for	10	minutes.	Cells	




















































Study	reference	 Name	 Description	 Manufacturer	 Per	test	
Chapter	3	 BD	GolgiPlug	 Contains	brefeldin	A	 BD	Biosciences	 1	µL	
Chapter	4	
BD	GolgiPlug		 Contains	brefeldin	A	 BD	Biosciences	 1	µL	
BD	GolgiStop	 Contains	monensin	 BD	Biosciences	 1	µL	
Chapter	5	 BD	GolgiPlug		 Contains	brefeldin	A	 BD	Biosciences	 1	µL	






Study	reference	 Name	 Description	 Manufacturer	 Per	test	
Chapter	3	 LIVE/DEAD	 Pacific	Blue	 LifeTechnologies	 1	µL	
Chapter	4	 LIVE/DEAD	 Pacific	Blue	 LifeTechnologies	 0.02	µL	
Chapter	5	 LIVE/DEAD	 Pacific	Orange	 LifeTechnologies	 0.02	µL	
	






Study	reference	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Chapter	3	
CD3	 HIT3a	 APC	 BD	Biosciences	 10	µL	
CD4	 SK3	 APC/Cy7	 BD	Biosciences	 5	µL	
CD8	 RPA-T8s	 PE/Cy7	 BD	Biosciences	 1	µL	
Integrinβ7	 FIB504	 PE/Cy5	 BD	Biosciences	 2	µL	
CD14	 M5E2	 HorizonV450	 BD	Biosciences	 2	µL	
CD19	 HIB19	 HorizonV450	 BD	Biosciences	 2	µL	
Chapter	4	
CD3	 OCT3	 BV/510	 BioLegend	 1	µL	
CD4	 SK3	 PE/Cy7	 BD	Biosciences	 1	µL	
CD8	 SK1	 APC/H7	 BD	Biosciences	 1	µL	
CD14	 MφP9	 HorizonV450	 BD	Biosciences	 1	µL	
CD19	 HIB19	 HorizonV450	 BD	Biosciences	 1	µL	
Chapter	5	
CD3	 SK7	 APC/H7	 BD	Biosciences	 1	µL	
CD4	 SK3	 PerCP/Cy5.5	 BioLegend	 1	µL	
CD8	 SK1	 BV/650	 BioLegend	 1	µL	
CD14	 MφP9	 APC/H7	 BD	Biosciences	 1	µL	
CD20	 2H7	 Pacific	Blue	 BioLegend	 1	µL	
CD161	 HP-3G10	 BV/785	 BioLegend	 1	µL	
TCRγδ	 11F2	 PE/Cy7	 BD	Biosciences	 1	µL	
Vα7.2	 3C10	 PE/Dazzle594	 BioLegend	 1	µL	
	
Cells	were	 incubated	for	20	minutes	at	room	temperature	 in	the	absence	of	 light.	150	µL	
wash	buffer	was	added	to	each	well	and	the	plates	centrifuged	at	330	g	for	10	minutes.	Cells	
were	 resuspened	 in	 100	 µL	 Cytofix/Cytoperm	 and	 incubated	 for	 20	 minutes	 at	 room	
temperature	 in	 the	absence	of	 light.	100	µL	Perm/Wash	was	added	 to	each	well	and	 the	





Study	reference	 Target	 Clone	 Fluorophore	 Manufacturer	 Volume	
Chapter	3	
IFN-γ	 B27	 AF700	 BD	Biosciences	 1	µL	
TNF-α	 MAb11	 AF488	 BD	Biosciences	 2.5	µL	
IL-2	 MQ1-17H12	 PE	 BD	Biosciences	 10	µL	
Chapter	4	
CD69	 FN50	 PE/CF594	 BD	Biosciences	 2	µL	
MIP-1β	 24006	 APC	 R&D	Systems	 2	µL	
IFN-γ	 B27	 AF700	 BD	Biosciences	 2	µL	
TNF-α	 MAb11	 AF488	 BD	Biosciences	 2	µL	
IL-2	 MQ1-17H12	 PE	 BD	Biosciences	 2	µL	
IL-17A	 eBio64DEC17	 PerCP/Cy5.5	 eBioscience	 2	µL	
Chapter	5	
IFN-γ	 4S.B3	 PE	 BioLegend	 2	µL	
TNF-α	 MAb11	 FITC	 BioLegend	 2	µL	
IL-17A	 N49-653	 AF700	 BD	Biosciences	 2	µL	
IL-4	 MP4-25D2	 BV711	 BD	Biosciences	 2	µL	
TGF-β	 TW4-6H10	 APC	 BioLegend	 2	µL	
	
Cells	were	 incubated	for	30	minutes	at	room	temperature	 in	the	absence	of	 light.	150	µL	
Perm/Wash	was	added	to	each	well	and	the	plates	centrifuged	at	330	g	for	10	minutes.	Cells	




Flow	 cytometric	 data	were	 acquired	 using	 either	 a	 LSR	 II	 flow	 cytometer	 (Chapter	 3	 and	
Chapter	4;	BD	Biosciences)	or	a	FACSAria	III	(Chapter	5;	BD	Biosciences).	Standard	procedures	
were	 used	 to	 maintain	 both	 machines	 and	 quality	 control	 was	 performed	 daily.	
Compensation	matrices	were	created	using	compensation	beads	(BD	Biosciences).	Analysis	

































added	to	each	well.	Plates	were	 incubated	at	 room	temperate	 for	a	 fixed	period	 (IgG;	90	
minutes	and	IgA;	30	minutes)	and	the	optical	density	of	each	well	measured	at	405	nm	using	
a	 FLUOstar	Omega	 ELISA	microplate	 reader	 (BMG	 Labtech).	 The	 average	 blank	 corrected	




100	 µL	 of	 carbonate-bicarbonate	 buffer	 containing	 25	 ng	 influenza	 hemagglutinin	 and	
neuraminidase	 antigens	 (Influvac	 containing,	 in	 equal	 quantities,	 a	 A/Brisbane/59/2007	
H1N1-like	 strain,	 a	 A/Brisbane/10/2007	 H3N2-like	 strain	 and	 a	 B/Brisbane/60/2008-like	



























added	to	each	well.	Plates	were	 incubated	at	 room	temperate	 for	a	 fixed	period	 (IgG;	90	
minutes	and	IgA;	30	minutes)	and	the	optical	density	of	each	well	measured	at	405	nm	using	
a	 FLUOstar	Omega	 ELISA	microplate	 reader	 (BMG	 Labtech).	 The	 average	 blank	 corrected	










days	 up	 to	 between	 28	 and	 56	 days	 (Salerno-Goncalves	 et	 al.,	 2010).	 It	 was,	 therefore,	
hypothesised	 that	during	 this	period	peripheral	T	cells	 traffic	 to	 the	gut.	The	day	18	 time	









Samples	 were	 acquired	 at	 these	 time	 points	 since	 changes	 in	 monocyte	 phenotype	 and	



































































reduction	 in	 output	 (-1;	 <80%	 of	 baseline),	 no	 change	 in	 output	 (0;	 between	
£80%	and	³120%	of	baseline),	or	increased	output	(+1;	<120%	of	baseline)	at	T1,	
T2	and	T3.	Linear	discriminant	analysis	of	principal	components	(DAPC)	was	used	












et	 al.,	 2002,	 Lundin	et	 al.,	 2002,	 Salerno-Goncalves	et	 al.,	 2004,	 Salerno-Goncalves	et	 al.,	
2005,	Salerno-Goncalves	et	al.,	2010,	McArthur	and	Sztein,	2012),	cellular	immunity	at	the	















identify	 mechanisms	 involved	 in	 the	 induction	 of	 protective	 immunity,	 which	 may	 be	




























































	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Viability	 Dead	cells	 N/A	 Pacific	Blue	 LifeTechnologies	 1	µL	
Extracellular	
CD3	 HIT3a	 APC	 BD	Biosciences	 10	µL	
CD4	 SK3	 APC/Cy7	 BD	Biosciences	 5	µL	
CD8	 RPA-T8s	 PE/Cy7	 BD	Biosciences	 1	µL	
Integrinβ7	 FIB504	 PE/Cy5	 BD	Biosciences	 2	µL	
CD14	 M5E2	 HorizonV450	 BD	Biosciences	 2	µL	
CD19	 HIB19	 HorizonV450	 BD	Biosciences	 2	µL	
Intracellular	
IFN-γ	 B27	 AF700	 BD	Biosciences	 1	µL	
TNF-α	 MAb11	 AF488	 BD	Biosciences	 2.5	µL	















following	vaccination.	We	also	measured	 levels	of	serum	IgG	and	 IgA	specific	to	 influenza	
virus,	a	 common	naturally	encountered	pathogen,	 to	assess	 the	 impact	of	vaccination	on	
humoral	 immunity	 to	 a	 heterologous	 pathogen.	 Influenza	 virus	 was	 selected	 since	 the	
majority,	if	not	all,	volunteers	would	have	been	exposed	to	this	pathogen	in	the	community.	




























was	 minimal,	 did	 not	 differ	 between	 vaccinated	 and	 unvaccinated	 volunteers	 and	 was	












the	 expression	 of	 CD4	 and	 CD8	 and	 the	 expression	 of	
interferon	γ	 (IFN-γ),	 tumor	necrosis	 factor	α	 (TNF-α),	and/or	
interleukin	 2	 (IL-2)	 assessed	 in	 non-stimulated	 and	 in	 live-
attenuated	Salmonella	 Typhi	strain	Ty21a	(Ty21a)-,	 influenza	
virus-	 and	 staphylococcal	 enterotoxin	 B	 (SEB)-stimulated	















for	 viability	 (LIVE/DEAD),	 CD19	 and	 CD14	 and	 gating	 on	 the	
negative	population.	T	cells	were	identified	according	to	the	
expression	 of	 CD3.	 T	 cells	 were	 classified	 according	 to	 the	
expression	of	CD4	and	CD8	and	the	expression	of	interferon	γ	
(IFN-γ),	tumor	necrosis	factor	α	(TNF-α),	and/or	interleukin	2	
(IL-2)	 assessed	 in	 non-stimulated	 and	 in	 live-attenuated	
Salmonella	 Typhi	 strain	 Ty21a	 (Ty21a)-,	 influenza	 virus-	 and	













frequency	 in	 the	unvaccinated	control	group	 (Figure	3.3).	These	data	suggest	 that	groups	
were	well	matched	for	prior	exposure	to	Ty21a	and	 influenza	virus	antigens	and	that	any	
differences	observed	thereafter	may	be	attributed	to	an	effect	of	vaccination	with	Ty21a.	




















.01,	 respectively;	 Figure	3.4A).	At	 the	colonic	mucosa,	 there	was	no	 significant	difference	
between	the	frequencies	of	Ty21a-responsive	or	heterologous	influenza	virus-responsive	T	
cells	in	vaccinated	volunteers,	compared	with	unvaccinated	volunteers	(Figure	3.4B).	
In	 peripheral	 blood,	 the	 frequency	 of	 Ty21a-responsive	 CD4+	 T	 cells	was	 4-fold	 higher	 in	





















been	 shown	 to	 correlate	 with	 vaccine-mediated	 protection	 against	 other	 intracellular	





volunteers,	 compared	 with	 unvaccinated	 volunteers	 (P=.006,	 P	 =	 .018	 and	 P	 =	 .031,	
respectively;	 Figure	 3.5A).	 The	 duodenal	 CD8+	 T-cell	 response	 to	 Ty21a	 antigens	 was,	 in	
contrast,	 largely	attributable	to	cells	expressing	just	one	cytokine	(P	=	.0004;	Figure	3.5A).	
Duodenal	CD4+	and	CD8+	T-cell	responses	to	influenza	virus	antigens	were	also	functionally	






In	 peripheral	 blood,	 the	 CD4+	 T-cell	 response	 to	 Ty21a	 antigens	 was	 functionally	




producing	 combinations	of	 IFN-γ,	 TNF-α	and	 IL-2	but	 that	no	one	 cytokine	predominated	
(Figure	3.6).	
		
Figure	 3.5.	 Combinations	 of	 antigen-specific	
cytokine	production	at	day	18	
The	 frequency	 of	 CD4+	 and	 CD8+	 live-attenuated	
Salmonella	Typhi	strain	Ty21a	(Ty21a)-responsive	and	
heterologous	 influenza	 virus-responsive	 populations	
expressing	one	(+),	two	(++),	or	three	(+++)	cytokines	
(interferon	 γ,	 tumor	 necrosis	 factor	 α,	 and/or	
interleukin	2)	above	background.	For	control	(C;	closed	
squares	and	circles	[duodenal	mucosa;	Ty21a	n	=	12,	
Influenza	 n	 =	 12]	 [peripheral	 blood;	 Ty21a	 n	 =	 12,	
Influenza	n	=	12])	and	vaccinated	(V;	open	squares	and	
circles	[duodenal	mucosa;	Ty21a	n	=	8,	Influenza	n	=	7]	
[peripheral	 blood;	 Ty21a	 n	 =	 9,	 Influenza	 n	 =	 9])	
volunteers,	measurements	were	made	at	the	duodenal	
mucosa	(A	and	B)	and	in	peripheral	blood	(C	and	D).	
Horizontal	 bars	 represent	mean	values	 (comparisons	










Figure	 3.6.	 Antigen-specific	 production	 of	
individual	cytokines	at	day	18	
The	 frequency	 of	 CD4+	 and	 CD8+	 live-attenuated	
Salmonella	Typhi	strain	Ty21a	(Ty21a)-responsive	and	
heterologous	 influenza	 virus-responsive	 populations	
expressing	IFN-γ,	TNF-α,	or	IL-2	above	background.	For	
control	 (C;	 closed	 squares	 and	 circles	 [duodenal	




Influenza	 n	 =	 9])	 volunteers,	 measurements	 were	













3.3.4. Correlations	 between	 cellular	 populations	 at	 the	 duodenal	
mucosa	
We	explored	the	relationship	between	the	generation	of	Ty21a-responsive	and	heterologous	





















	 DUODENAL	MUCOSA	 PERIPHERAL	BLOOD	 SERUM	
Ty21a	 Influenza	 Ty21a	 Influenza	 S.	Typhi	LPS	 Influenza	
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Integrin	 β7	 plays	 a	 prominent	 role	 in	 mucosal	 cellular	 immune	 defence;	 α4β7	 facilitates	
peripheral	 trafficking	 to	 the	 intestinal	 mucosa	 and	 αεβ7	 helps	 maintain	 resident	
intraepithelial	 lymphocyte	 populations	 (Berlin	 et	 al.,	 1993,	 Cepek	 et	 al.,	 1994).	 Since	
duodenal	CD4+	and	CD8+	T-cell	responses	to	Ty21a	and	influenza	virus	antigens	were	closely	
correlated,	we	assessed	the	cellular	capacity	for	mucosal	homing	and	residence,	which	is	a	
















cell	 population	 (P	 =	 .002;	 Figure	 3.7B),	 expression	 intensity	 among	 the	 influenza	 virus-
responsive	CD4+	T-cell	subpopulation	was	not	different	from	that	among	the	total	CD4+	T-
cell	 population.	 Integrin	 β7	 expression	 intensity	 among	 the	 Ty21a-responsive	 and	
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to	 either	 antigen	 in	 either	 T-cell	 subset.	 This	 suggests	 that	 duodenal	 responses	 were	
compartmentalised	 to	 the	 embryological	midgut,	 which	 includes	 the	 terminal	 ileum,	 the	




























responsive	 and	 influenza	 virus-responsive	 cells,	 compared	 with	 total	 cell	 populations,	 in	
peripheral	blood	and	at	the	intestinal	mucosa.	Multiphasic	peripheral	CD8+	T-cell	responses	
have	 previously	 been	 described	 and	 attributed	 to	 the	 trafficking	 of	 immune	 cells	 from	
peripheral	blood	to	the	mucosa	(Salerno-Goncalves	et	al.,	2010,	McArthur	and	Sztein,	2012).	
In	 keeping	 with	 this,	 integrin	 β7	 expression	 among	 peripheral	 CD8+	 T	 cells,	 particularly	
antigen-specific	subpopulations,	was	more	intense	than	that	among	peripheral	CD4+	T	cells.	
Integrin	β7	expression	among	CD4+	T-cell	subsets	was	highly	polarised,	being	relatively	low	
among	 peripheral	 subsets	 and	 high	 among	 duodenal	 subsets.	 Differential	 integrin	 β7	
expression	among	antigen-specific	CD4+	T-cell	populations	may	ensure	that	some	peripheral	



















been	 demonstrated	 that	 the	 generation	 of	 immunoglobulin	 following	 oral	 vaccination	 is	
dependent	upon	α4β7	(Wyant	et	al.,	2015).	Thus,	the	close	association	between	cellular	and	
humoral	 immune	 responses	 suggests	 that	 the	 strength	 of	 each	 volunteer’s	 cellular	 and	
humoral	 response	 to	 vaccination	 was	 influenced	 by	 a	 mucosal	 mechanism,	 possibly	 the	
expression	intensity	of	α4β7	and/or	MAdCAM-1	at	the	time	of	vaccination.		
It	is	possible	that,	through	TLR	engagement,	vaccination	may	have	non-specifically	activated	
mucosal	 antigen-presenting	 cells	 and	 T	 cells,	 resulting	 in	 enhanced	 cytokine	 production	
following	experimental	 re-stimulation	 (Lore	et	 al.,	 2003,	Caron	et	 al.,	 2005).	However,	 as	




to	 the	 unvaccinated	 volunteers,	 we	 believe	 this	 is	 unlikely	 to	 be	 the	 primary	 factor	
responsible	for	the	observed	heterologous	cellular	response.	Owing	to	the	invasive	nature	
of	endoscopic	biopsy,	we	were	limited	to	sampling	from	intestinal	sites	at	a	single	time	point.	
Data	 presented	 here	 and	 elsewhere	 (McArthur	 and	 Sztein,	 2012)	 indicate	 that	 the	
assessment	of	mucosal	immunity	at	alternate	time	points	could	provide	further	insight	into	







Taken	 together,	our	data	demonstrate	 that	oral	 vaccination	with	Ty21a	generates	Ty21a-
responsive	T	cells	as	well	as	heterologous	influenza	virus-responsive	T	cells	at	the	duodenal	
mucosa.	We	propose	that	heterologous	influenza	virus-responsive	T	cells	previously	primed	















attenuated	 oral	 vaccine	 candidate,	 CVD	 909,	 has	 demonstrated	 the	 capacity	 to	 generate	











An	 increased	 understanding	 of	 the	 longevity	 of	 immune	 responses	 both	 at	 the	 intestinal	
mucosa	and	 in	peripheral	blood	may	allow	us	 to	 identify	 functional	correlates	of	vaccine-
mediated	 protection,	 which	 are	 currently	 unknown.	 Here,	 we	 have	 assessed	 cellular	




















































	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Viability	 Dead	cells	 N/A	 Pacific	Blue	 LifeTechnologies	 0.02	µL	
Extracellular	
CD3	 OCT3	 BV/510	 BioLegend	 1	µL	
CD4	 SK3	 PE/Cy7	 BD	Biosciences	 1	µL	
CD8	 SK1	 APC/H7	 BD	Biosciences	 1	µL	
CD14	 MφP9	 HorizonV450	 BD	Biosciences	 1	µL	
CD19	 HIB19	 HorizonV450	 BD	Biosciences	 1	µL	
Intracellular	
CD69	 FN50	 PE/CF594	 BD	Biosciences	 2	µL	
MIP-1β	 24006	 APC	 R&D	Systems	 2	µL	
IFN-γ	 B27	 AF700	 BD	Biosciences	 2	µL	
TNF-α	 MAb11	 AF488	 BD	Biosciences	 2	µL	
IL-2	 MQ1-17H12	 PE	 BD	Biosciences	 2	µL	












Volunteers	who	had	previously	been	vaccinated	as	part	of	past	 studies	were	 recalled	 for	
sampling.	 The	 period	 between	 vaccination	 and	 sampling	 varied,	 with	 the	median	 period	
between	vaccination	and	sampling	at	1.5	years	(Table	4.4).	
Table	4.4.	Volunteer	vaccination	and	sampling	information	













1975)	and,	 in	 field	trials,	humoral	 responses	to	LPS	were	shown	to	correlate	with	vaccine	
efficacy	(Levine	et	al.,	1989).	We	measured	levels	of	serum	anti-LPS	IgG	and	IgA	in	vaccinated	
volunteers	and	controls.		
At	 day	 0	 (baseline),	 levels	 of	 anti-LPS	 IgG	 and	 IgA	did	not	 differ	 between	 vaccinated	 and	
unvaccinated	volunteers	(Figure	4.1).	Among	vaccinated	volunteers,	levels	of	anti-LPS	serum	
IgG	 were	 6-fold	 higher	 at	 day	 11	 (T1),	 5-fold	 higher	 at	 day	 18	 (T2)	 and	 2-fold	 higher	 at	
approximately	1.5	years	(T3)	([bootstrapped	95%	confidence	interval	(CI)	based	on	arbitrary	




Similarly,	 among	 vaccinated	 volunteers,	 levels	 of	 anti-LPS	 serum	 IgA	 were	 3-fold	 higher	
among	vaccinated	volunteers	at	day	11	and	2-fold	at	day	18	(-97104	to	-27173	and	-41746	


























Dot	 plots	 are	 shown	 for	 cells	 isolated	 from	 the	 duodenal	
mucosa.	 Dead	 cells	 were	 removed	 by	 staining	 for	 viability	
(LIVE/DEAD)	 and	 gating	 on	 the	 negative	 population.	 T	 cells	
were	 identified	 according	 to	 the	 expression	 of	 CD3.	 T	 cells	
were	classified	according	to	the	expression	of	CD4	and	CD8	and	
the	 expression	 of	 IFN-γ,	 TNF-α,	 IL2,	 IL-17A,	 and	 MIP-1β	















according	 to	 the	 expression	 of	 CD3.	 T	 cells	 were	 classified	
according	to	the	expression	of	CD4	and	CD8	and	the	expression	















Since	 overnight	 fasting,	 required	 prior	 to	 endoscopy,	 is	 known	 to	 influence	 cytokine	
production	in	peripheral	blood	in	response	to	re-stimulation	with	bacterial	antigens	(van	den	





















Polyfunctional	 T	 cells,	 defined	 as	 cells	 that	 express	 multiple	 cytokines/chemokines	
simultaneously,	 have	 been	 shown	 to	 correlate	 with	 vaccine-mediated	 protection	 against	
other	intracellular	infections	(Darrah	et	al.,	2007,	Kannanganat	et	al.,	2007).	After	comparing	
the	 proportions	 of	 antigen-responsive	 populations,	 we	 assessed	 the	 cytokine	 expression	
profile	 of	 vaccinated	 volunteers	 with	 that	 of	 unvaccinated	 volunteers.	 Specifically,	 we	
assessed	 the	 functionality	 of	 the	 response	 as	 well	 as	 individual	 cytokine/chemokine	
production.		
Consistent	with	our	published	data	(Pennington	et	al.,	2016),	responses	among	CD8+	T	cells	
comprised	 far	 fewer	polyfunctional	 subpopulations,	 both	 at	 the	duodenal	mucosa	 and	 in	
peripheral	blood	(Figure	4.4	and	4.6).	Of	the	cytokines/chemokines	studied	here,	MIP1β	was	










Figure	 4.4.	 Combinations	 of	 antigen-specific	
cytokine	production	at	the	duodenal	mucosa	
The	 frequency	 of	 CD4+	 and	 CD8+	 Salmonella	 Typhi	
strain	Ty21a-responsive	(A	and	B)	and	FliC-responsive	
(C	 and	 D)	 populations	 expressing	 one	 (+),	 two	 (++),	
three	 (+++),	 four	 (++++)	 or	 five	 (+++++)	
cytokines/chemokines	(IFN-γ	±	TNF-α	±	IL-2	±	IL-17A	±	
MIP-1β)	 above	 background.	 For	 control	 (C;	 closed	
squares	and	diamonds	 [Ty21a	 n	=	9,	FliC	n	=	5])	and	
vaccinated	(V;	open	squares	and	diamonds	[Ty21a	n	=	












Figure	 4.5.	 Antigen-specific	 production	 of	
individual	cytokines	at	the	duodenal	mucosa	
The	 frequency	of	CD4+	and	CD8+	Ty21a-responsive	 (A	
and	 B)	 and	 FliC-responsive	 (C	 and	 D)	 populations	
expressing	IFN-γ,	TNF-α,	IL-2,	IL-17A,	or	MIP-1β	above	



















suggests	 that	 the	 increased	 frequency	 of	 polyfunctional	 Ty21a-responsive	 CD4+	 T	 cells	
generated	in	response	to	vaccination	persists	for	at	least	1.5	years.	
The	frequency	of	FliC-responsive	CD4+	T	cells	expressing	one	and	two	cytokines/chemokines	
was	higher	 in	vaccinated	volunteers	 than	controls	 (-3.1896	 to	 -0.52607	and	 -0.03688	 to	 -
0.00417,	respectively;	Figure	4.6).	Analysis	by	individual	cytokine	revealed	that	the	frequency	




Figure	 4.6.	 Combinations	 of	 antigen-specific	
cytokine	production	in	peripheral	blood	
The	 frequency	of	CD4+	and	CD8+	Ty21a-responsive	 (A	


















Figure	 4.7.	 Antigen-specific	 production	 of	
individual	cytokines	in	peripheral	blood	
The	frequency	of	CD4+	and	CD8+	Ty21a-responsive	 (A	
and	 B)	 and	 FliC-responsive	 (C	 and	 D)	 populations	
expressing	IFN-γ,	TNF-α,	IL-2,	IL-17A,	or	MIP-1β	above	


































the	 duodenal	mucosa	 18	days	 following	 vaccination	with	 Ty21a.	Here,	 approximately	 1.5	
years	following	vaccination,	no	response	was	observed	at	the	duodenal	mucosa	in	either	T-






indeed,	 polyfunctional	 CD8+	 T	 cells	 are	 associated	 with	 protection	 against	 typhoid	 fever	
(Fresnay	 et	 al.,	 2016).	 Consistent	 with	 our	 previously	 published	 data	 (Pennington	 et	 al.,	
2016),	 the	frequency	of	responsive	cells	 tended	to	be	higher	amongst	CD4+	T	cells;	 this	 is	






responsive	 CD4+	 T	 cells	 tended	 to	 express	 just	 one	 or	 two	 cytokines/chemokines.	 This	
suggests	 that	 the	 FliC	 antigen	 is	 not	 responsible	 for	 the	 generation	 of	 polyfunctional	
responses	and	that	other	antigens,	which	are	present	in	the	heat-killed	Ty21a	preparation,	
are	responsible	for	the	induction	of	polyfunctional	responses.		
The	 fact	 that	 duodenal	 responses	 are	 transient,	 may	 indicate	 that	 the	 composition	 of	
mucosal	 T-cell	 populations	 is	 subject	 to	 considerable	 change.	 This	 may	 be	 due	 to	 the	
relatively	high	frequency	with	which	different	pathogens	are	encountered	at	the	intestinal	
mucosa.	It	has	previously	been	demonstrated	that	peripheral	responses,	generated	through	
vaccination	 with	 Ty21a,	 with	 increased	 mucosal	 homing	 potential,	 persist	 in	 peripheral	
circulation	 for	 at	 least	 90	 days	 (Wahid	 et	 al.,	 2008).	 Thus,	 if	 S.	 Typhi	 were	 to	 be	 re-
encountered	 at	 the	 intestinal	mucosa,	 long-lived	 peripheral	 cell	 populations	would	 likely	
possess	 an	 enhanced	 capacity	 to	 rapidly	migrate	 to	 the	mucosal	 surface	 through	 innate	
signalling	and	homing	receptor	up	regulation	(De	Calisto	et	al.,	2012).	







the	 strength	 of	 early	 responses	 steadily	 declined.	 Similarly,	 early	 anti-LPS	 IgA	 responses	
steadily	declined,	being	significantly	higher	at	day	11	and	day	18,	but	returning	to	a	 level	
which	was	comparable	with	baseline	at	1.5	years.	In	humans,	memory	B-cells	can	essentially	







for	prior	exposure	 to	S.	Typhi.	We	have	previously	observed	 that	heterologous	 influenza-


























Epidemiological	 evidence	 has	 demonstrated	 that	 live-attenuated	 vaccines	 can	 reduce	 all-
cause	mortality	(Benn	et	al.,	2013,	Goodridge	et	al.,	2016).	The	strongest	evidence	has	been	





modifications	 among	 innate	 immune	 cell	 populations	 (Ramirez-Carrozzi	 et	 al.,	 2006,	
Ramirez-Carrozzi	et	al.,	2009,	Krawczyk	et	al.,	2010,	Pantel	et	al.,	2014).	These	changes	may	
manifest	 themselves	 in	 the	 form	 of	 phenotypic	 variation	 among	 circulating	 innate	 cell	
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al.,	 2015).	We	 have	 also	 observed	 enhanced	 cellular	 responses	 to	 influenza-virus	 at	 the	
duodenal	mucosa	18	days	following	vaccination	with	Ty21a	(Pennington	et	al.,	2016).	We,	












• Vaccination	 with	 Ty21a	 would	 enhance	 the	 expression	 of	 surface	 receptors	
engaged	by	Ty21a	on	circulating	CD14+	monocytes	
































Full	 details	 can	 be	 found	 in	 section	 2.5.8.	 Dyes	 and	 antibodies	 used	 for	 purposes	 of	
phenotypic	analysis	of	monocytes	in	this	chapter	include:	
Table	5.2.	Dyes	and	antibodies	used	for	analysis	of	monocyte	phenotype	
	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Viability	 Dead	cells	 N/A	 PacificOrange	 LifeTechnologies	 0.02	µL	
Extracellular	
CD14	 FcγRIII	 PerCP/Cy5.5	 BD	Biosciences	 3.5	µL	
CD16	 HI10a	 APC/Cy7	 BioLegend	 3.5	µL	
CD64	 TS1/18	 BV605	 BioLegend	 3.5	µL	
CD18	 ICRF44	 PE/Cy7	 BioLegend	 3.5	µL	
CD11b	 Bu15	 AF700	 BD	Biosciences	 3.5	µL	
CD11c	 6H6	 Pacific	Blue	 BioLegend	 3.5	µL	
CD123	 19.2	 BV711	 BioLegend	 3.5	µL	
CD206	 HTA125	 PE/CF594	 BD	Biosciences	 3.5	µL	
CD284	 624915	 APC	 BioLegend	 3.5	µL	
CD285	 201A	 FITC	 R&D	Systems	 3.5	µL	




























	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Viability	 Dead	cells	 N/A	 PacificOrange	 LifeTechnologies	 0.02	µL	
Extracellular	
CD3	 SK7	 APC/H7	 BD	Biosciences	 1	µL	
CD4	 SK3	 PerCP/Cy5.5	 BioLegend	 1	µL	
CD8	 SK1	 BV/650	 BioLegend	 1	µL	
CD14	 MφP9	 APC/H7	 BD	Biosciences	 1	µL	
CD20	 2H7	 Pacific	Blue	 BioLegend	 1	µL	
CD161	 HP-3G10	 BV/785	 BioLegend	 1	µL	
TCRγδ	 11F2	 PE/Cy7	 BD	Biosciences	 1	µL	
Vα7.2	 3C10	 PE/Dazzle594	 BioLegend	 1	µL	
Intracellular	
IFN-γ	 4S.B3	 PE	 BioLegend	 2	µL	
TNF-α	 MAb11	 FITC	 BioLegend	 2	µL	
IL-17A	 N49-653	 AF700	 BD	Biosciences	 2	µL	
IL-4	 MP4-25D2	 BV711	 BD	Biosciences	 2	µL	















CD14,	 CD16	 (FcRIII),	 CD18	 (integrin	 β2),	 CD64	 (FcγRI),	 CD123	 (IL-3RA),	 CD206	 (mannose	
receptor),	CD303	(BDCA-2),	HLA-DR,	TLR-4	and	TLR-5	on	the	surface	of	non-stimulated	CD14+	
monocytes	by	flow	cytometry.	A	sequential	gating	strategy	was	used	to	identify	populations	
of	 interest	 (Figure	 5.1).	 We	 compared	 the	 phenotypic	 properties	 of	 cells	 isolated	 from	






5.2).	 Expression	 of	 all	 receptors	 among	 vaccinated	 volunteers	 were	 comparable	 with	
baseline	at	month	6.	No	change	in	the	expression	intensity	of	CD14,	CD18,	CD123,	CD206	
and	HLA-DR	was	observed	among	the	vaccinated	group	at	any	time	point.	Among	control	
group	 volunteers,	 increased	 expression	 of	 CD11b	was	 observed	 at	 day	 14	 (P	 =	 .002).	 No	




































heat-killed	 C.	 albicans,	 split-viron	 influenza	 virus;	 PPD	 from	M.	 tuberculosis	 and	 tetanus	
toxoid.	We	then	assessed	the	production	of	IFN-γ,	IL-4,	IL-17A,	TGF-β	and	TNF-α	by	B	cells,	
CD4+	 T	 cells,	 CD8+	 T	 cells,	 monocytes,	MAIT	 cells,	 and	 TCRγδ	 cells	 by	 flow	 cytometry.	 A	
sequential	 gating	 strategy	 was	 used	 to	 identify	 populations	 of	 interest	 (Figure	 5.4).	 The	
frequency	of	each	population	positive	 for	each	 cytokine	was	multiplied	by	 the	 geometric	
mean	fluorescence	intensity	for	each	cytokine-positive	population	above	background	–	this	



















blood.	 (A)	 Dead	 cells	 were	 removed	 by	 staining	 for	 viability	
(LIVE/DEAD)	and	gating	on	the	negative	population.	The	CD3	positive	
population	 were	 defined	 as	 follows;	 TCRγδ	 cells	 were	 identified	
according	 to	 the	 expression	 of	 TCRγδ;	mucosal	 associated	 invariant	
(MAIT)	cells	were	identified	according	to	the	expression	of	CD161	and	
Vα7.2	not	already	identified	as	TCRγδ	cells;	CD4+	and	CD8+	T	cells	were	
identified	 according	 to	 the	 expression	 of	 CD4	 and	 CD8	 not	 already	
identified	as	TCRγδ	cells	or	MAIT	cells.	(B)	Monocytes	were	identified	
according	 to	 the	 expression	 of	 CD14	 as	 well	 as	 the	 intermediate	
expression	of	CD4	and	CD20.	 The	expression	of	 interferon	γ	 (IFN-γ),	
interleukin	 4	 (IL-4),	 IL-17A,	 transforming	 growth	 factor	 β	 (TGF-β),	
and/or	tumor	necrosis	factor	α	(TNF-α)	assessed	in	non-stimulated	and	
in	 heat-killed	 live-attenuated	 Salmonella	 Typhi	 strain	 Ty21a;	 heat-
killed	 Candida	 albicans;	 split-viron	 influenza;	 purified	 protein	

















the	 following	 stimuli;	 heat-killed	 live-attenuated	 Salmonella	 Typhi	 strain	 Ty21a	 (Ty21a);	 heat-killed	 Candida	 albicans	 (C.	



























Here	we	 have	 demonstrated	 that	 oral	 vaccination	with	 S.	 Typhi	 strain	 Ty21a	 can	 induce	
upregulation	 of	 CD11b,	 CD11c,	 CD16,	 CD64,	 CD303,	 TLR-4	 and	 TLR-5	 among	 CD14+	
monocytes	for	at	 least	3	months.	These	changes	are	indicative	of	the	induction	of	trained	
immunity.	 We	 have	 further	 demonstrated	 that	 vaccination	 with	 Ty21a	 alters	 cytokine	











phagocytic	 function	 and	 antigen-presentation	 as	 well	 as	 enhanced	 chemotaxic	 potential	
(Solovjov	et	al.,	2005,	Georgakopoulos	et	al.,	2008,	Cheeseman	et	al.,	2016).	These	changes	
likely	 contribute	 towards	 the	 non-specific	 beneficial	 effects	 conferred	 through	 the	
generation	of	trained	immunity.	
Differences	in	expression	were	observed	for	at	least	3	months	following	vaccination.	Since	
monocytes	 typically	 only	 persist	 in	 circulation	 for	 a	 single	 day	 (Yona	 et	 al.,	 2013),	 it	 is	
reasonable	 to	 hypothesise	 that	 phenotypic	 changes	 observed	 as	 long	 as	 3	months	 after	








Many	 factors	 influence	 human	 cytokine	 production;	 indeed,	 variation	 has	 been	 reported	
over	a	period	as	short	as	24	hours	(Edgar	et	al.,	2016).	We	have	observed	temporal	variation	
in	cytokine	production	in	the	unvaccinated	control	group	over	a	6	month	period.	It	is	possible	
that	 changes	 in	 the	 control	 group	may	be	 the	 result	 of	 seasonal	 variation	 in	 the	 relative	
frequency	with	which	different	pathogens	are	encountered.	In	order	to	ensure	that	effects,	
particularly	 those	 surrounding	 heterologous	 responses,	 are	 not	 wrongly	 attributed	 to	
vaccination	or	 clinical	 intervention,	 it	 is	 imperative	 that	 future	 studies	 include	 temporally	
matched-controls	in	order	to	account	for	temporal	variation,	as	was	the	case	in	this	study.	
This	 is	 important	since	temporal	variation	may,	at	 least	 in	part,	contribute	toward	altered	
cytokine	production	which	has	been	observed	elsewhere	(Kleinnijenhuis	et	al.,	2014).	
BCG,	 measles	 containing	 vaccines	 and	 oral	 polio	 vaccines	 have	 all	 been	 associated	 with	
reductions	in	all-cause	mortality	(Aaby	et	al.,	2010,	Flanagan	et	al.,	2013,	Aaby	et	al.,	2014,	
Sorup	et	al.,	2014,	Lund	et	al.,	2015,	de	Castro	et	al.,	2015);	however,	it	is	unclear	whether	
these	 observations	 are	 the	 result	 of	 altered	 cytokine	 production.	 It	 has	 previously	 been	
demonstrated	that	cytokine	production	in	response	to	in	vitro	stimulation	with	heterologous	
antigens	is	altered	following	vaccination	with	BCG	(Kleinnijenhuis	et	al.,	2014).	It	is	unclear	
whether	 changes	 in	 cytokine	 production	 are	 the	 result	 of	 altered	 antigen-presentation	
occurring	 in	 vitro,	 or	 whether	 these	 changes	 reflect	 altered	 immune	 cell	 population	











cytokine	 responses	 to	 heterologous	 antigens.	 Unfortunately,	 since	we	 did	 not	 anticipate	
temporal	variation	within	the	control	group,	we	lacked	the	statistical	power	to	perform	the	
appropriate	statistical	comparisons	to	provide	detailed	insight	into	the	populations	driving	










the	 generation	of	 trained	 immunity.	Although	BCG,	measles	 containing	 vaccines	 and	oral	
polio	 vaccines	 have	 all	 been	 associated	 with	 the	 induction	 of	 trained	 immunity	 and	 a	
reduction	in	all-cause	mortality	(Aaby	et	al.,	2010,	Flanagan	et	al.,	2013,	Aaby	et	al.,	2014,	
Sorup	et	al.,	2014,	Lund	et	al.,	2015,	de	Castro	et	al.,	2015),	the	low	cost	and	ease	with	which	
Ty21a	may	 be	 administered	makes	 it	 a	 particularly	 attractive	 platform	 for	 development.	







































mucosal	 immune	defence,	 and	 that	 Ty21a	may	be	used	 to	 confer	 benefits	 beyond	 those	
specific	to	S.	Typhi.	





administered	 vaccines	 targeting	 mucosal	 pathogens,	 the	 direct	 assessment	 of	 mucosal	
immune	defence	is	a	more	relevant	measure	of	immunogenicity,	which	may	more	accurately	
reflect	 some	 aspects	 of	 oral	 vaccine	 efficacy.	 The	 mechanisms	 through	 which	 adaptive	





were	 not	 observed	 at	 the	 colonic	 mucosa.	 The	 total	 surface	 area	 of	 the	 adult	 human	
gastrointestinal	mucosa	is	estimated	to	be	between	30	and	40	m2	(Helander	and	Fandriks,	














Cellular	 immune	 responses	were	 observed	 to	 persist	 in	 peripheral	 blood,	 but	 not	 at	 the	
duodenal	 mucosa	 approximately	 1.5	 years	 following	 vaccination.	 Due	 to	 the	 non-sterile	




6.1.5. Trained	 immunity	 is	 conferred	 and	 immune	 responses	 to	
heterologous	antigens	are	altered	
Monocyte	phenotype	and	cytokine	expression	profiles	are	altered	following	vaccination	with	
Ty21a.	Data	presented	here	are	 the	 first	which	demonstrate	 that	Ty21a	generates	 innate	
immune	memory.	Phenotypic	analysis	of	monocytes	demonstrated	increased	expression	of	
surface	molecules	engaged	by	Ty21a,	as	well	as	other	associated	which	are	indicative	of	a	
heightened	 immune	 state.	 Similar	 effects	 have	 previously	 been	 observed	 following	
vaccination	with	BCG	(Kleinnijenhuis	et	al.,	2014).	The	low	cost	and	ease	with	which	Ty21a	
may	 be	 administered,	 compared	 with	 other	 vaccines	 which	 have	 been	 shown	 to	 confer	
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innate	 immune	 memory,	 makes	 Ty21a	 a	 particularly	 attractive	 platform	 for	 further	
development	(Aaby	et	al.,	2010,	Flanagan	et	al.,	2013,	Aaby	et	al.,	2014,	Sorup	et	al.,	2014,	
Lund	 et	 al.,	 2015,	 de	 Castro	 et	 al.,	 2015).	 The	 administration	 of	 Ty21a	 alongside	 other	
vaccines	could	improve	their	efficacy.	Further	study	is	warranted	to	explore	the	impact	of	
Ty21a	on	immune	responses	to	co-administered	vaccine	antigens.	Evidence	would	indicate	
that,	 for	 example,	 administration	 of	 Ty21a	 could	 enhance	 responses	 to	 parenterally-
administered	vaccines	through	TLR	engagement	(Oh	et	al.,	2014).	
6.2. Future	work	
Based	 on	 the	 data	 presented	 within	 this	 thesis,	 further	 investigation	 to	 more	 fully	
characterise	 the	complex	 interactions	between	S.	Typhi	and	 its	human	host	 is	warranted.	
Some	possible	avenues	of	exploration	include:	
6.2.1. The	assessment	of	peripheral	 and	mucosal	 immune	cellular	
responses	to	wild-type	S.	Typhi	





Since	 the	 first	 models	 of	 controlled	 human	 infection	 were	 discontinued,	 technological	
advancements	have	made	it	possible	to	safely	acquire	previously	inaccessible	samples.	The	
acquisition	 and	 interrogation	 of	 these	 samples	 would	 allow	 for	 a	 more	 comprehensive	
assessment	of	host-pathogen	 interaction.	 The	 controlled	S.	Typhi	human	 infection	model	
now	 established	 at	 the	 University	 of	 Oxford,	 will	 utilise	 these	 advancements	 to	 study	
pathogenic	 wild-type	 S.	 Typhi	 in	 its	 natural	 host,	 both	 peripherally	 and	 at	 the	 intestinal	
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The	 assessment	 of	 the	 human	 transcriptome	 following	 exposure	 to	 Ty21a	 both	 at	 the	
intestinal	mucosa	and	in	peripheral	blood	could	yield	important	insight	into	the	mechanisms	
responsible	 for	 the	 generation	 of	 protective	 immune	 responses.	 Further,	 analysis	 of	 the	





at	 the	 intestinal	 mucosa	 and	 in	 peripheral	 blood	 would	 be	 of	 great	 interest.	 A	 greater	
understanding	 of	 factors	which	 influence	 host	 susceptibility	 to	 disease	 could	 lead	 to	 the	
development	 of	more	 effective	 vaccines	 targeting	 this	 pathogen.	 Transcriptomic	 analysis	











experimental	 human	 pneumococcal	 carriage	 has	 been	 used	 to	 successfully	 assess	 the	
efficacy	of	13-valent	pneumococcal	conjugate	vaccine	(PCV)	on	pneumococcal	colonisation,	
at	 a	 fraction	 of	 the	 cost	 associated	with	 full-scale	 field	 trials	 (Collins	 et	 al.,	 2015).	 If,	 for	
example,	 the	 administration	 of	 Ty21a	 alongside	 PCV	 resulted	 in	 increased	 vaccine	










into	 the	generation	of	mucosal	 immune	defence	and	 insight	 into	cellular	dynamics	at	 the	
intestinal	mucosa.	We	have	also	demonstrated	that	Ty21a	can	confer	additional	benefits,	
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